HD-OPM Archive
Hashtags

#colchicine

18 posts

Colchicine 0.5 mg cut plaque volume by over 1% in one year on CT angiography (Budoff)

May 11, 2025 · Louis Nervegna ♥ 20 · 💬 37 ↩ 9 Plaque, CAC & CT angiography

Louis highlights a Budoff-led CCTA trial in which low-dose colchicine reduced percent atheroma volume by over 1% in a year, with lower CRP and a slowing of calcified plaque. He contrasts this with the Keto-CTA study, where PAV rose 0.8% on a keto diet. Budoff notes it was a small study but supports colchicine in chronic stable coronary disease.

Six strategies shown to regress plaque in human randomized trials

Feb 27, 2025 · Louis Nervegna ♥ 27 · 💬 10 ↩ 3 Plaque, CAC & CT angiography

Louis lists strategies with RCT evidence for plaque regression: major weight loss, a Mediterranean or DASH diet, LDL-lowering drugs, colchicine, exercise and high-dose EPA. He notes six RCTs show diet can regress plaque and that Ornish's results resembled PREDIMED and CORDIOPREV, while Esselstyn's data are not from RCTs.

2025 ACC statement: inflammation is actionable in CVD, with universal hsCRP screening

Oct 09, 2025 · Gokhan Can ♥ 15 · 💬 13 Inflammation & CRP

Summarises the 2025 ACC Scientific Statement (JACC) concluding the inflammation-ASCVD link is now clinically actionable. It recommends universal hsCRP screening in primary and secondary prevention alongside cholesterol, notes IL-6 and fibrinogen also predict risk, and says CT perivascular fat attenuation is promising but not routine. It contrasts this with a more cautious 2002 CDC/AHA workshop.

Plaque reduction: statins, PCSK9 inhibitors and ezetimibe have the strongest evidence

May 18, 2024 · Gokhan Can ♥ 32 · 💬 5 Plaque, CAC & CT angiography

Ranks interventions for regressing or stabilizing atherosclerotic plaque. Statins, PCSK9 inhibitors and ezetimibe have the strongest trial evidence, with high-dose EPA and pioglitazone fairly good; colchicine, aged garlic, Centella, pine bark, nattokinase and plant-based diets are promising but need rigorous imaging RCTs, and evidence for exercise, L-arginine and vitamin K2 is limited.

Colchicine may work partly by inhibiting IL-11, a lifespan-linked pro-fibrotic cytokine

Jul 26, 2024 · Louis Nervegna ♥ 13 · 💬 15 ↩ 4 Inflammation & CRP

The poster speculates that because colchicine, the first approved anti-inflammatory heart drug, has anti-fibrotic effects (it was studied in pulmonary fibrosis), it may act partly through IL-11 inhibition. Blocking IL-11 extended mouse lifespan by 25%, and anti-IL-11 therapies are entering pulmonary fibrosis trials. This is a hypothesis.